126 related articles for article (PubMed ID: 21978513)
1. [Recessive dystrophic bullous epidermolysis: Is the etiological treatment at the streetcorner?].
Dereure O
Ann Dermatol Venereol; 2011 Oct; 138(10):710-1. PubMed ID: 21978513
[No Abstract] [Full Text] [Related]
2. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT).
Hum Gene Ther Clin Dev; 2014 Jun; 25(2):65-6. PubMed ID: 24933565
[No Abstract] [Full Text] [Related]
4. Gene therapy for recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Hovnanian A
Dermatol Clin; 2010 Apr; 28(2):361-6, xii. PubMed ID: 20447504
[TBL] [Abstract][Full Text] [Related]
5. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa.
Goto M; Sawamura D; Ito K; Abe M; Nishie W; Sakai K; Shibaki A; Akiyama M; Shimizu H
J Invest Dermatol; 2006 Apr; 126(4):766-72. PubMed ID: 16439972
[TBL] [Abstract][Full Text] [Related]
6. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa.
Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G
Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108
[TBL] [Abstract][Full Text] [Related]
7. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
[TBL] [Abstract][Full Text] [Related]
8. HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa.
Nagy N; Almaani N; Tanaka A; Lai-Cheong JE; Techanukul T; Mellerio JE; McGrath JA
J Invest Dermatol; 2011 Aug; 131(8):1771-4. PubMed ID: 21471992
[No Abstract] [Full Text] [Related]
9. An RNA-targeted therapy for dystrophic epidermolysis bullosa.
Peking P; Koller U; Duarte B; Murillas R; Wolf S; Maetzig T; Rothe M; Kocher T; García M; Brachtl G; Schambach A; Larcher F; Reichelt J; Bauer JW; Murauer EM
Nucleic Acids Res; 2017 Sep; 45(17):10259-10269. PubMed ID: 28973459
[TBL] [Abstract][Full Text] [Related]
10. Novel COL7A1 splice site mutation in severe generalized recessive dystrophic epidermolysis bullosa.
Jeon IK; Kim SE; Kim SC
J Dermatol; 2014 Apr; 41(4):350-1. PubMed ID: 24533879
[No Abstract] [Full Text] [Related]
11. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
Cutlar L; Greiser U; Wang W
Exp Dermatol; 2014 Jan; 23(1):1-6. PubMed ID: 24107073
[TBL] [Abstract][Full Text] [Related]
12. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients.
Goto M; Sawamura D; Nishie W; Sakai K; McMillan JR; Akiyama M; Shimizu H
J Invest Dermatol; 2006 Dec; 126(12):2614-20. PubMed ID: 16778792
[TBL] [Abstract][Full Text] [Related]
13. Murine type VII collagen distorts outcome in human skin graft mouse model for dystrophic epidermolysis bullosa.
Bremer J; Kramer D; Eichhorn DS; Gostyński A; Diercks GFH; Jonkman MF; van den Akker PC; Pasmooij AMG
Exp Dermatol; 2019 Oct; 28(10):1153-1155. PubMed ID: 30019435
[TBL] [Abstract][Full Text] [Related]
14. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.
Woodley DT; Krueger GG; Jorgensen CM; Fairley JA; Atha T; Huang Y; Chan L; Keene DR; Chen M
J Invest Dermatol; 2003 Nov; 121(5):1021-8. PubMed ID: 14708601
[TBL] [Abstract][Full Text] [Related]
15. COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.
Hainzl S; Peking P; Kocher T; Murauer EM; Larcher F; Del Rio M; Duarte B; Steiner M; Klausegger A; Bauer JW; Reichelt J; Koller U
Mol Ther; 2017 Nov; 25(11):2573-2584. PubMed ID: 28800953
[TBL] [Abstract][Full Text] [Related]
16. A recurrent nonsense mutation occurring as a de novo event in a patient with recessive dystrophic epidermolysis bullosa.
Cuadrado-Corrales N; Sánchez-Jimeno C; García M; Ayuso C; De Lucas R; Vicario JL; Conti CJ; Zambruno G; Escamez MJ; Del Rio M
Dermatology; 2011; 223(3):219-21. PubMed ID: 21849769
[No Abstract] [Full Text] [Related]
17. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.
Murauer EM; Gache Y; Gratz IK; Klausegger A; Muss W; Gruber C; Meneguzzi G; Hintner H; Bauer JW
J Invest Dermatol; 2011 Jan; 131(1):74-83. PubMed ID: 20720561
[TBL] [Abstract][Full Text] [Related]
18. Meganuclease-Mediated COL7A1 Gene Correction for Recessive Dystrophic Epidermolysis Bullosa.
Izmiryan A; Danos O; Hovnanian A
J Invest Dermatol; 2016 Apr; 136(4):872-875. PubMed ID: 26897595
[No Abstract] [Full Text] [Related]
19. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.
Wong T; Gammon L; Liu L; Mellerio JE; Dopping-Hepenstal PJ; Pacy J; Elia G; Jeffery R; Leigh IM; Navsaria H; McGrath JA
J Invest Dermatol; 2008 Sep; 128(9):2179-89. PubMed ID: 18385758
[TBL] [Abstract][Full Text] [Related]
20. Fibroblasts as target cells for DEB gene therapy.
Chen M; Woodley DT
J Invest Dermatol; 2006 Apr; 126(4):708-10. PubMed ID: 16541096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]